Paul M O'byrne

List of Publications by Year
in descending order

369 papers	34,203 citations	4955 84 h-index	4112 175 g-index
385 all docs	385 docs citations	385 times ranked	18817 citing authors

#	Article	IF	Citations
1	Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal, 2008, 31, 143-178.	3.1	2,510
2	Development and validation of a questionnaire to measure asthma control. European Respiratory Journal, 1999, 14, 902.	3.1	2,019
3	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
4	Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. New England Journal of Medicine, 1997, 337, 1405-1411.	13.9	1,478
5	Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. New England Journal of Medicine, 2009, 360, 985-993.	13.9	1,260
6	Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. New England Journal of Medicine, 1999, 340, 197-206.	13.9	778
7	Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. Journal of Allergy and Clinical Immunology, 1981, 68, 347-355.	1.5	707
8	Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet, The, 2003, 361, 1071-1076.	6.3	705
9	Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. New England Journal of Medicine, 2014, 370, 2102-2110.	13.9	668
10	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	3.1	636
11	Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 129-136.	2.5	593
12	Effect of Long-term Treatment with an Inhaled Corticosteroid (Budesonide) on Airway Hyperresponsiveness and Clinical Asthma in Nonsteroid-dependent Asthmatics. The American Review of Respiratory Disease, 1990, 142, 832-836.	2.9	580
13	Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 588-594.	2.5	486
14	Bronchoalveolar Cell Profiles of Asthmatic and Nonasthmatic Subjects. The American Review of Respiratory Disease, 1987, 136, 379-383.	2.9	464
15	Inhaled Combined Budesonideâ€“Formoterol as Needed in Mild Asthma. New England Journal of Medicine, 2018, 378, 1865-1876.	13.9	453
16	Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D₄â€“Receptor Antagonist. New England Journal of Medicine, 1990, 323, 1736-1739.	13.9	412
17	Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. Journal of Allergy and Clinical Immunology, 2016, 137, 75-86.e8.	1.5	388
18	Severe Exacerbations and Decline in Lung Function in Asthma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 19-24.	2.5	377

#	Article	IF	Citations
19	A new perspective on concepts of asthma severity and control. European Respiratory Journal, 2008, 32, 545-554.	3.1	372
20	As-Needed Budesonideâ€“Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine, 2018, 378, 1877-1887.	13.9	368
21	Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2015, 3, 692-701.	5.2	318
22	Safety and efficacy of a <scp>CXCR</scp>2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placeboâ€controlled clinical trial. Clinical and Experimental Allergy, 2012, 42, 1097-1103.	1.4	300
23	GINA guidelines on asthma and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 102-12.	2.7	271
24	Airway Responsiveness to Leukotrienes C4 and D4 and to Methacholine in Patients with Asthma and Normal Controls. New England Journal of Medicine, 1986, 315, 480-484.	13.9	253
25	Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils.. Journal of Experimental Medicine, 1994, 180, 711-715.	4.2	228
26	Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. American Journal of Medicine, 2004, 116, 338-344.	0.6	225
27	Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6.	1.5	219
28	Changes in the Cellular Profile of Induced Sputum after Allergen-induced Asthmatic Responses. The American Review of Respiratory Disease, 1992, 145, 1265-1269.	2.9	218
29	Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1007-1014.	2.5	215
30	Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2016, 4, 797-806.	5.2	202
31	The trials and tribulations of IL-5, eosinophils, and allergic asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 503-508.	1.5	196
32	Relationship between quality of life and clinical status in asthma: a factor analysis. European Respiratory Journal, 2004, 23, 287-291.	3.1	189
33	Urinary leukotriene E4 levels during early and late asthmatic responsesâ€. Journal of Allergy and Clinical Immunology, 1990, 86, 211-220.	1.5	187
34	The origin of airway hyperresponsiveness. Journal of Allergy and Clinical Immunology, 1986, 78, 825-832.	1.5	181
35	Dysfunction and Remodeling of the Mouse Airway Persist after Resolution of Acute Allergen-Induced Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 526-535.	1.4	178
36	A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nature Medicine, 2007, 13, 862-867.	15.2	174

#	Article	IF	Citations
37	The Global Initiative for Asthma (GINA): 25â€…years later. European Respiratory Journal, 2019, 54, 1900598.	3.1	174
38	Adult Asthma Consensus Guidelines Update 2003. Canadian Respiratory Journal, 2004, 11, 9A-18A.	0.8	171
39	Airway Hyperresponsiveness. Chest, 2003, 123, 411S-416S.	0.4	165
40	Allergen-induced Asthmatic Responses: Relationship Between Increases in Airway Responsiveness and Increases in Circulating Eosinophils, Basophils, and Their Progenitors. The American Review of Respiratory Disease, 1991, 143, 331-335.	2.9	164
41	Recent Advances in the Pathophysiology of Asthma. Chest, 2010, 137, 1417-1426.	0.4	164
42	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet, The, 2017, 389, 157-166.	6.3	158
43	Type 2 Cytokines in the Pathogenesis of Sustained Airway Dysfunction and Airway Remodeling in Mice. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 860-867.	2.5	155
44	Evaluation of Asthma Control by Physicians and Patients: Comparison with Current Guidelines. Canadian Respiratory Journal, 2002, 9, 417-423.	0.8	141
45	Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 952-958.	2.5	139
46	Asthma and Exercise-Induced Bronchoconstriction in Athletes. New England Journal of Medicine, 2015, 372, 641-648.	13.9	134
47	Regular use of inhaled albuterol and the allergen-induced late asthmatic response. Journal of Allergy and Clinical Immunology, 1995, 96, 44-49.	1.5	132
48	The paradoxes of asthma management: time for a new approach?. European Respiratory Journal, 2017, 50, 1701103.	3.1	130
49	Epithelial-Derived Cytokines in Asthma. Chest, 2017, 151, 1338-1344.	0.4	129
50	Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 700-712.	2.5	128
51	The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma. Journal of Allergy and Clinical Immunology, 2008, 121, 1167-1174.	1.5	126
52	Immunostimulatory Sequences Regulate Interferon-inducible Genes but not Allergic Airway Responses. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 15-20.	2.5	124
53	Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. Journal of Allergy and Clinical Immunology, 2016, 138, 1051-1059.	1.5	122
54	Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health, 2019, 7, e613-e623.	2.9	122

#	Article	IF	Citations
55	Leukotrienes in the Pathogenesis of Asthma. Chest, 1997, 111, 27S-34S.	0.4	121
56	Allergen-Induced Increase in Airway Responsiveness, Airway Eosinophilia, and Bone-Marrow Eosinophil Progenitors in Mice. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 473-479.	1.4	116
57	Effects of Montelukast and Budesonide on Airway Responses and Airway Inflammation in Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1212-1217.	2.5	115
58	Antileukotrienes in the Treatment of Asthma. Annals of Internal Medicine, 1997, 127, 472.	2.0	114
59	Cysteinyl Leukotrienes Promote Human Airway Smooth Muscle Migration. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 738-742.	2.5	114
60	A role for sensory nerves in the late asthmatic response. Thorax, 2012, 67, 19-25.	2.7	109
61	Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Science Translational Medicine, 2014, 6, 243ra85.	5.8	108
62	Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma. Chest, 2006, 129, 1478-1485.	0.4	107
63	Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 349-356.e13.	1.5	107
64	EAACI position statement on asthma exacerbations and severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1520-1531.	2.7	107
65	The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. Journal of Allergy and Clinical Immunology, 2002, 110, 96-101.	1.5	106
66	Inhaled allergen bronchoprovocation tests. Journal of Allergy and Clinical Immunology, 2013, 132, 1045-1055.e6.	1.5	106
67	Risks of Pneumonia in Patients with Asthma Taking Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 589-595.	2.5	103
68	Formoterol Compared with Beclomethasone and Placebo on Allergen-induced Asthmatic Responses. The American Review of Respiratory Disease, 1992, 146, 1156-1160.	2.9	101
69	The Safety of Long-Acting Î²-Agonists among Patients with Asthma Using Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1009-1016.	2.5	99
70	Allergen-induced airway responses. European Respiratory Journal, 2015, 46, 819-831.	3.1	99
71	Asthma progression and mortality: the role of inhaled corticosteroids. European Respiratory Journal, 2019, 54, 1900491.	3.1	96
72	Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. European Respiratory Journal, 1998, 11, 828-834.	3.1	95

#	Article	IF	Citations
73	The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. Journal of Allergy and Clinical Immunology, 2003, 112, 331-338.	1.5	94
74	Increases in airway eosinophils and interleukin-5 with minimal bronchoconstriction during repeated low-dose allergen challenge in atopic asthmatics. European Respiratory Journal, 1998, 11, 821-827.	3.1	93
75	Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma. , 2017, 169, 104-112.		93
76	Sputum CD34+IL-5RÎ±+Cells Increase after Allergen. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 573-577.	2.5	91
77	Rapid response of circulating myeloid dendritic cells to inhaled allergen in asthmatic subjects. Clinical and Experimental Allergy, 2002, 32, 818-823.	1.4	89
78	<scp>OX</scp>40L blockade and allergenâ€induced airway responses in subjects with mild asthma. Clinical and Experimental Allergy, 2014, 44, 29-37.	1.4	89
79	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. Journal of Allergy and Clinical Immunology, 2015, 135, 1457-1464.e4.	1.5	88
80	Reproducibility of allergen-induced early and late asthmatic responses. Journal of Allergy and Clinical Immunology, 1995, 95, 1191-1195.	1.5	86
81	Sputum Eosinophils and the Response of Exercise-Induced Bronchoconstriction to Corticosteroid in Asthma. Chest, 2008, 133, 404-411.	0.4	86
82	Risks of Long-Acting Beta-Agonists in Achieving Asthma Control. New England Journal of Medicine, 2009, 360, 1671-1672.	13.9	86
83	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. Chest, 2013, 144, 1222-1229.	0.4	86
84	Development and implementation of guidelines in allergic rhinitis â€“ an ARIAâ€CA²LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	2.7	85
85	Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine. Journal of Allergy and Clinical Immunology, 1989, 83, 913-920.	1.5	84
86	The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 56-59.	2.7	84
87	Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respiratory Research, 2011, 12, 140.	1.4	84
88	Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. Immunology, 2003, 109, 536-546.	2.0	83
89	Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1008-1013.	1.5	83
90	The Poorly Explored Impact of Uncontrolled Asthma. Chest, 2013, 143, 511-523.	0.4	81

#	Article	IF	Citations
91	Allergen-induced Increases in Bone Marrow T Lymphocytes and Interleukin-5 Expression in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 883-889.	2.5	80
92	Kinetics of Bone Marrow Eosinophilopoiesis and Associated Cytokines after Allergen Inhalation. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 565-572.	2.5	80
93	Measuring asthma control: a comparison of three classification systems. European Respiratory Journal, 2010, 36, 269-276.	3.1	80
94	Provoked models of asthma: what have we learnt?. Clinical and Experimental Allergy, 2009, 39, 181-192.	1.4	79
95	Measuring efficacy and safety of different inhaled corticosteroid preparationsâ˜†â˜†â˜†…. Journal of Allergy and Clinical Immunology, 1998, 102, 879-886.	1.5	78
96	Combined Analysis of Asthma Safety Trials of Long-Acting Î²₂-Agonists. New England Journal of Medicine, 2018, 378, 2497-2505.	13.9	76
97	Aqueous beclomethasone diproprionate nasal spray: Regular versus â€œas requiredâ€•use in the treatment of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 1990, 86, 380-386.	1.5	74
98	Effect of Interferon-Î³on Allergic Airway Responses in Interferon-Î³â€“deficient Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 451-456.	2.5	74
99	Cytokines or Their Antagonists for the Treatment of Asthma. Chest, 2006, 130, 244-250.	0.4	74
100	Corticosteroidâ€•induced gene expression in allergenâ€•challenged asthmatic subjects taking inhaled budesonide. British Journal of Pharmacology, 2012, 165, 1737-1747.	2.7	73
101	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax, 2014, 69, 312-319.	2.7	73
102	Allergen-induced airway hyperresponsiveness. Journal of Allergy and Clinical Immunology, 1988, 81, 119-127.	1.5	72
103	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal, 2014, 43, 773-782.	3.1	72
104	Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction. Journal of Allergy and Clinical Immunology, 2017, 139, 771-779.e10.	1.5	72
105	Montelukast Treatment Attenuates the Increase in Myofibroblasts Following Low-Dose Allergen Challenge. Chest, 2006, 130, 741-753.	0.4	71
106	Extracellular matrix regulates human airway smooth muscle cell migration. European Respiratory Journal, 2004, 24, 545-551.	3.1	69
107	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the Î²₂agonist vilanterol administered once daily for 52â€…weeks in patients â‰¥12â€…years old with asthma: a randomised trial. Thorax, 2013, 68, 513-520.	2.7	69
108	The allergen bronchoprovocation model: an important tool for the investigation of new asthma antiâ€•inflammatory therapies. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1101-1110.	2.7	68

#	Article	IF	Citations
109	Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled Î² 2 -Agonists in Achieving Asthma Control. Chest, 2008, 134, 1192-1199.	0.4	68
110	Global differences in lung function by region (PURE): an international, community-based prospective study. Lancet Respiratory Medicine,the, 2013, 1, 599-609.	5.2	68
111	Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 649-659.e2.	2.0	68
112	IL-25 and IL-25 Receptor Expression on Eosinophils from Subjects with Allergic Asthma. International Archives of Allergy and Immunology, 2014, 163, 5-10.	0.9	67
113	Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4â€“receptor antagonist cinalukastâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1997, 99, 210-215.	1.5	66
114	Prolonged Protection against Methacholine-induced Bronchoconstriction by the Inhaled Î²₂-Agonist Formoterol. The American Review of Respiratory Disease, 1991, 143, 998-1001.	2.9	65
115	Efficacy and Cost Benefit of Inhaled Corticosteroids in Patients Considered to Have Mild Asthma in Primary Care Practice. Canadian Respiratory Journal, 1996, 3, 169-175.	0.8	65
116	Allergen Challenge Increases Cell Traffic between Bone Marrow and Lung. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 759-767.	1.4	63
117	Severe asthma: future treatments. Clinical and Experimental Allergy, 2012, 42, 706-711.	1.4	63
118	Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 1594-1602.	1.5	63
119	Bronchoconstriction Stimulated by Airway Cooling. The American Review of Respiratory Disease, 1983, 128, 440-443.	2.9	60
120	Repeatability of allergen-induced airway inflammationâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 66-71.	1.5	59
121	Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 73-79.	1.5	59
122	Cigarette smoke aggravates experimental colitis in rats. Gastroenterology, 1999, 117, 877-883.	0.6	58
123	Myeloid and plasmacytoid dendritic cells in induced sputum after allergen inhalation in subjects with asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 133-139.	1.5	58
124	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Research, 2011, 12, 38.	1.4	58
125	Reassessing the Th2 cytokine basis of asthma. Trends in Pharmacological Sciences, 2004, 25, 244-248.	4.0	57
126	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	2.7	57

#	Article	IF	Citations
127	A GM-CSF/IL-33 Pathway Facilitates Allergic Airway Responses to Sub-Threshold House Dust Mite Exposure. PLoS ONE, 2014, 9, e88714.	1.1	57
128	The Demise of Antiâ€"IL-5 for Asthma, or Not. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1059-1060.	2.5	56
129	The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 101, 342-348.	1.5	54
130	Pharmacological management of mild or moderate persistent asthma. Lancet, The, 2006, 368, 794-803.	6.3	54
131	Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. Journal of Allergy and Clinical Immunology, 2002, 109, 789-793.	1.5	53
132	Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma. PLoS ONE, 2020, 15, e0228544.	1.1	52
133	Progenitor egress from the bone marrow after allergen challenge: Role of stromal cellâ€"derived factor 1Î± and eotaxin. Journal of Allergy and Clinical Immunology, 2005, 115, 501-507.	1.5	51
134	A pilot randomised clinical trial ofÂmepolizumab in COPD with eosinophilic bronchitis. European Respiratory Journal, 2017, 49, 1602486.	3.1	51
135	Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge modelâ˜†â˜†â˜†â˜…â˜……. Journal of Allergy and Clinical Immunology, 1997, 100, 65-70.	1.5	50
136	Omalizumab and the immune system: an overview of preclinical and clinical data. Annals of Allergy, Asthma and Immunology, 2002, 89, 132-138.	0.5	50
137	Enhanced Expression of GM-CSF in Differentiating Eosinophils of Atopic and Atopic Asthmatic Subjects. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 55-62.	1.4	49
138	Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 404-406.	1.5	46
139	Effect of a single day of increased as-needed budesonideâ€"formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine,the, 2021, 9, 149-158.	5.2	46
140	Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma. JAMA - Journal of the American Medical Association, 2021, 325, 2466.	3.8	46
141	Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight, 2022, 7, .	2.3	46
142	Morphometric Analysis of Mouse Airways After Chronic Allergen Challenge. Laboratory Investigation, 2003, 83, 1285-1291.	1.7	45
143	Decreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challenge. BMC Genomics, 2012, 13, 655.	1.2	45
144	The Effects of Inhaled Budesonide on Lung Function in Smokers and Nonsmokers With Mild Persistent Asthma. Chest, 2009, 136, 1514-1520.	0.4	44

#	Article	IF	Citations
145	Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting Î²2-agonist, in patients with mild asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 1217-1221.	1.5	44
146	Therapeutic strategies to reduce asthma exacerbations. Journal of Allergy and Clinical Immunology, 2011, 128, 257-263.	1.5	44
147	Airway Inflammation and Hyperresponsiveness. The American Review of Respiratory Disease, 1987, 136, S35-S37.	2.9	43
148	Beclomethasone given after the early asthmatic response inhibits the late response and the increased methacholine responsiveness and cromolyn does not. Journal of Allergy and Clinical Immunology, 1993, 91, 1163-1168.	1.5	43
149	Basophil and eosinophil differentiation in allergic reactions. Journal of Allergy and Clinical Immunology, 1994, 94, 1135-1141.	1.5	43
150	Predictors of Loss of Asthma Control Induced by Corticosteroid Withdrawal. Canadian Respiratory Journal, 2006, 13, 129-133.	0.8	43
151	Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omegaâ€3 fatty acids. Molecular Nutrition and Food Research, 2013, 57, 1378-1389.	1.5	43
152	The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects. Pulmonary Pharmacology and Therapeutics, 2016, 41, 34-39.	1.1	43
153	IL-25 Receptor Expression on Airway Dendritic Cells after Allergen Challenge in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 957-964.	2.5	43
154	Prostaglandin F2Î± increases responsiveness of pulmonary airways in dogs. Prostaglandins, 1984, 28, 537-543.	1.2	42
155	The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 915-920.	2.5	42
156	Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. Journal of Allergy and Clinical Immunology, 2005, 116, 285-291.	1.5	42
157	Single-dose desloratadine and montelukast and allergen-induced late airway responses. European Respiratory Journal, 2009, 33, 1302-1308.	3.1	42
158	Screening of Stimulants Including Designer Drugs in Urine Using a Liquid Chromatography Tandem Mass Spectrometry System. Journal of Analytical Toxicology, 2013, 37, 64-73.	1.7	41
159	Simplified quantitation of myeloid dendritic cells in peripheral blood using flow cytometry. , 2000, 40, 50-59.		40
160	Fluticasone Furoateâ€“Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 553-561.	2.0	40
161	Mediators, airway responsiveness, and asthma. Journal of Allergy and Clinical Immunology, 1985, 76, 272-276.	1.5	39
162	Early intervention of recent onset mild persistent asthma in children aged under 11 yrs: the Steroid Treatment As Regular Therapy in early asthma (START) trial. Pediatric Allergy and Immunology, 2006, 17, 7-13.	1.1	39

#	Article	IF	Citations
163	The effects of indomethacin on refractoriness following exercise both with and without a bronchoconstrictor response. European Respiratory Journal, 1994, 7, 2174-2178.	3.1	38
164	Therapeutic interventions in severe asthma. World Allergy Organization Journal, 2016, 9, 40.	1.6	38
165	The Effects of Intranasal Budesonide on Allergen-induced Production of Interleukin-5 and Eotaxin, Airways, Blood, and Bone Marrow Eosinophilia, and Eosinophil Progenitor Expansion in Sensitized Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 146-153.	2.5	37
166	The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. Journal of Allergy and Clinical Immunology, 2007, 119, 322-327.	1.5	37
167	Efficacy and safety of fluticasone furoate 100ÂÎ¼g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respiratory Medicine, 2014, 108, 41-49.	1.3	37
168	Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 788-795.e1.	1.5	37
169	Histamine Bronchoconstriction Reduces Airway Responsiveness in Asthmatic Subjects. The American Review of Respiratory Disease, 1988, 137, 1323-1325.	2.9	36
170	Protective Effects of Fluticasone on Allergen-Induced Airway Responses and Sputum Inflammatory Markers. Canadian Respiratory Journal, 2000, 7, 313-319.	0.8	36
171	Interleukin-18 expression, CD8+ T cells, and eosinophils in lungs of nonsmokers with fatal asthma. Annals of Allergy, Asthma and Immunology, 2014, 112, 23-28.e1.	0.5	36
172	The Effect of Omega-3 Fatty Acids on Bronchial Hyperresponsiveness, Sputum Eosinophilia, and Mast Cell Mediators in Asthma. Chest, 2015, 147, 397-405.	0.4	36
173	Airway Hyperresponsiveness and Calcium Handling by Smooth Muscle. Chest, 2002, 121, 621-624.	0.4	35
174	Different profiles of T-cell IFN-Î³ and IL-12 in allergen-induced early and dual responders with asthma. Journal of Allergy and Clinical Immunology, 2005, 115, 1004-1009.	1.5	35
175	Effect of different asthma treatments on risk of cold-related exacerbations. European Respiratory Journal, 2011, 38, 584-593.	3.1	35
176	Fluticasone furoate (FF)/vilanterol (100/25â€‰mcg or 200/25â€‰mcg) or FF (100â€‰mcg) in persistent asthma. Journal of Asthma, 2015, 52, 1073-1083.	0.9	35
177	The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1105-1114.	2.5	35
178	Allergen-induced Airway Inflammation and Its Therapeutic Intervention. Allergy, Asthma and Immunology Research, 2009, 1, 3.	1.1	34
179	A Nonsteroidal Glucocorticoid Receptor Agonist Inhibits Allergen-induced Late Asthmatic Responses. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 161-167.	2.5	34
180	The burden of exacerbations in mild asthma: a systematic review. ERJ Open Research, 2020, 6, 00359-2019.	1.1	33

#	Article	IF	Citations
181	A New Role for Histamine H2-Receptors in Asthmatic Airways. The American Review of Respiratory Disease, 1988, 138, 784-788.	2.9	32
182	The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study. Contemporary Clinical Trials, 2001, 22, 405-419.	2.0	32
183	Allergen-induced Changes in Bone Marrow and Airway Dendritic Cells in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 169-177.	2.5	32
184	Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE). The Lancet Global Health, 2017, 5, e168-e176.	2.9	31
185	An anti-inflammatory drug (BW755C) inhibits airway hyperresponsiveness induced by ozone in dogs. Journal of Allergy and Clinical Immunology, 1985, 76, 162-166.	1.5	30
186	Î²2 DÃ©jÃ Vu. Chest, 2006, 129, 3-5.	0.4	30
187	Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology, 2007, 119, 1332-1336.	1.5	30
188	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given â€˜as neededâ€™ in mild asthma: study protocols for two randomised controlled trials. Trials, 2017, 18, 12.	0.7	30
189	Toward personalization of asthma treatment according to trigger factors. Journal of Allergy and Clinical Immunology, 2020, 145, 1529-1534.	1.5	30
190	Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging. ERJ Open Research, 2021, 7, 00160-2021.	1.1	30
191	Acute, but Not Resolved, Influenza A Infection Enhances Susceptibility to House Dust Mite-Induced Allergic Disease. Journal of Immunology, 2009, 182, 3095-3104.	0.4	29
192	Influenza A facilitates sensitization to house dust mite in infant mice leading to an asthma phenotype in adulthood. Mucosal Immunology, 2011, 4, 682-694.	2.7	29
193	The interaction between bronchoconstriction and cough in asthma. Thorax, 2017, 72, 1144-1146.	2.7	29
194	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. Respirology, 2020, 25, 804-815.	1.3	29
195	Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1139-1145.	2.7	28
196	The aqueous stability of bupropion. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 376-381.	1.4	28
197	Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 696-703.	1.5	28
198	Th17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response. Allergy, Asthma and Clinical Immunology, 2014, 10, 32.	0.9	28

#	Article	IF	Citations
199	Effects of interleukinâ€6 receptor blockade on allergenâ€induced airway responses in mild asthmatics. Clinical and Translational Immunology, 2019, 8, e1044.	1.7	28
200	The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements. European Respiratory Journal, 2001, 17, 581-588.	3.1	27
201	IL-10 production in circulating T cells differs between allergen-induced isolated early and dual asthmatic responders. Journal of Allergy and Clinical Immunology, 2002, 109, 281-286.	1.5	27
202	Understanding Allergic Asthma from Allergen Inhalation Tests. Canadian Respiratory Journal, 2007, 14, 414-418.	0.8	27
203	Phosphodiesterase-4 inhibition in COPD. Lancet, The, 2009, 374, 665-667.	6.3	27
204	Isosorbide-Based Aspirin Prodrugs: Integration of Nitric Oxide Releasing Groups. Journal of Medicinal Chemistry, 2009, 52, 6588-6598.	2.9	27
205	Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate.. Thorax, 1982, 37, 913-917.	2.7	25
206	Myeloid dendritic cells type 2 after allergen inhalation in asthmatic subjects. Clinical and Experimental Allergy, 2014, 44, 921-929.	1.4	25
207	An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma. Respiratory Medicine, 2004, 98, 1146-1154.	1.3	24
208	Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy. Journal of Allergy and Clinical Immunology, 2005, 115, 745-750.	1.5	24
209	Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 537-542.	2.7	24
210	Decreased CTLA4+ and Foxp3+ CD25highCD4+ Cells in Induced Sputum from Patients with Mild Atopic Asthma. Allergology International, 2013, 62, 203-213.	1.4	24
211	Onceâ€daily fluticasone furoate 50Âmcg in mildâ€toâ€moderate asthma: a 24â€week placeboâ€controlled randomized trial. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1522-1530.	2.7	24
212	The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. European Respiratory Journal, 2019, 53, 1802250.	3.1	24
213	The effect of oral prostaglandin E1 on airway responsiveness in asthmatic subjects. Pulmonary Pharmacology, 1989, 2, 121-124.	0.5	23
214	Eicosanoids and Asthma. Annals of the New York Academy of Sciences, 1994, 744, 251-261.	1.8	23
215	The Effect of Treatment with Budesonide or PGE2In Vitroon Allergen-induced Increases in Canine Bone Marrow Progenitors. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 634-641.	1.4	23
216	Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial. Contemporary Clinical Trials, 2001, 22, 420-437.	2.0	23

#	Article	IF	Citations
217	The Potential Role of Aspiration in the Asthmatic Airway. Chest, 2017, 151, 1272-1278.	0.4	23
218	Expression of IL-33 and TSLP and Their Receptors in Asthmatic Airways after Inhaled Allergen Challenge. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 805-807.	2.5	23
219	Anti-allergic therapies: effects on eosinophil progenitors. , 2002, 95, 63-72.		22
220	Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 397-403.	1.5	22
221	Lung Homing of Endothelial Progenitor Cells in Humans with Asthma after Allergen Challenge. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 771-778.	2.5	22
222	Interleukin-18 and interleukin-18 receptor-Â expression in allergic asthma. European Respiratory Journal, 2011, 38, 981-983.	3.1	22
223	The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction. Journal of Allergy and Clinical Immunology, 2012, 130, 535-539.e3.	1.5	22
224	Measuring Eosinophils to Make Treatment Decisions in Asthma. Chest, 2016, 150, 485-487.	0.4	22
225	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3069-3077.e6.	2.0	22
226	The pathogenesis of severe asthma: A consensus report from the workshop on pathogenesis. Journal of Allergy and Clinical Immunology, 1987, 80, 428-437.	1.5	21
227	Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 863-870.	1.5	21
228	The effect of IVXâ€0142, a heparinâ€derived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1195-1201.	2.7	21
229	Daily Inhaled Corticosteroid Treatment Should Be Prescribed for Mild Persistent Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 410-412.	2.5	20
230	Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge. Journal of Allergy and Clinical Immunology, 2018, 141, 1495-1498.e9.	1.5	20
231	Daily Inhaled Corticosteroid Treatment Should Not Be Prescribed for Mild Persistent Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 412-414.	2.5	19
232	Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 731-736.	2.7	19
233	Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. Clinical and Experimental Allergy, 2006, 36, 1417-1424.	1.4	19
234	Gene-Metabolite Expression in Blood Can Discriminate Allergen-Induced Isolated Early from Dual Asthmatic Responses. PLoS ONE, 2013, 8, e67907.	1.1	19

#	Article	IF	Citations
235	T Helper 17 Cells and Related Cytokines after Allergen Inhalation Challenge in Allergic Asthmatics. International Archives of Allergy and Immunology, 2014, 165, 27-34.	0.9	19
236	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respiratory Research, 2014, 15, 88.	1.4	19
237	Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma. Clinical and Translational Allergy, 2018, 8, 5.	1.4	19
238	Breastfeeding and risk of childhood asthma: a systematic review and meta-analysis. ERJ Open Research, 2021, 7, 00504-2021.	1.1	19
239	The effect of inhaled hexamethonium bromide and atropine sulphate on airway responsiveness to histamine. Journal of Allergy and Clinical Immunology, 1985, 76, 97-103.	1.5	18
240	Pharmacologic Interventions to Reduce the Risk of Asthma Exacerbations. Proceedings of the American Thoracic Society, 2004, 1, 105-108.	3.5	18
241	Comparison of the Effect of Low-Dose Ciclesonide and Fixed-Dose Fluticasone Propionate and Salmeterol Combination on Long-term Asthma Control. Chest, 2011, 139, 311-318.	0.4	18
242	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. Journal of Negative Results in BioMedicine, 2014, 13, 9.	1.4	18
243	Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 450-462.	2.5	18
244	In Vivo-to-In Silico Iterations to Investigate Aeroallergen-Host Interactions. PLoS ONE, 2008, 3, e2426.	1.1	18
245	Inhaled Î²2-Agonists in the Treatment of Asthma. New England Journal of Medicine, 1996, 335, 886-888.	13.9	17
246	Shifting of Immune Responsiveness to House Dust Mite by Influenza A Infection: Genomic Insights. Journal of Immunology, 2012, 188, 832-843.	0.4	17
247	Allergen-Induced Increases in Interleukin-25 and Interleukin-25 Receptor Expression in Mature Eosinophils from Atopic Asthmatics. International Archives of Allergy and Immunology, 2016, 170, 234-242.	0.9	17
248	Positioning As-needed Budesonideâ€“Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. Annals of the American Thoracic Society, 2021, 18, 2007-2017.	1.5	17
249	Modulation of Î²1-integrins on hemopoietic progenitor cells after allergen challenge in asthmatic subjects. Journal of Allergy and Clinical Immunology, 2008, 122, 803-810.	1.5	16
250	Asthma Management by Monitoring Sputum Neutrophil Count. Chest, 2008, 134, 628-630.	0.4	16
251	Peripheral Blood Gene Expression Changes during Allergen Inhalation Challenge in Atopic Asthmatic Individuals. Journal of Asthma, 2012, 49, 219-226.	0.9	16
252	The presence of Aspergillus fumigatus in asthmatic airways is not clearly related to clinical disease severity. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1146-1154.	2.7	16

#	Article	IF	Citations
253	The effects of H2-receptor antagonists on exercise refractoriness in asthma. Journal of Allergy and Clinical Immunology, 1992, 90, 125-126.	1.5	15
254	Hemopoietic Mechanisms in Allergic Airway Inflammation. International Archives of Allergy and Immunology, 1998, 117, 155-159.	0.9	15
255	The management of mild asthma. European Respiratory Journal, 2021, 57, 2003051.	3.1	15
256	Dose-response Protective Effect of Salbutamol on Methacholine Airway Responsiveness using Pressurized Metered Dose Inhalers and Turbuhalers. Canadian Respiratory Journal, 1998, 5, 119-123.	0.8	14
257	Exhaled nitric oxide in guideline-based asthma management. Lancet, The, 2008, 372, 1015-1017.	6.3	14
258	Sputum inflammatory cells and allergen-induced airway responses in allergic asthmatic subjects. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1075-1080.	2.7	14
259	Myeloid dendritic cells type 2 in allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1322-1326.	2.7	14
260	Role of Monoclonal Antibodies in the Treatment of Asthma. Canadian Respiratory Journal, 2013, 20, 23-25.	0.8	14
261	Allergen provocation tests in respiratory research: building on 50â€...years of experience. European Respiratory Journal, 2022, 60, 2102782.	3.1	14
262	Inhaled Corticosteroids for Asthma: Common Clinical Quandaries. Journal of Asthma, 2003, 40, 107-118.	0.9	13
263	Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction. European Respiratory Journal, 2021, 57, 2000839.	3.1	13
264	Effect of intranasal corticosteroid treatment on allergenâ€induced changes in group 2 innate lymphoid cells in allergic rhinitis with mild asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2797-2808.	2.7	12
265	Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework. European Respiratory Review, 2021, 30, 210104.	3.0	12
266	Global guidelines for asthma management: summary of the current status and future challenges. , 2010, 120, 511-7.		12
267	Increased Levels of Airway Neutrophils Reduces the Inhibitory Effects of Inhaled Glucocorticosteroids on Allergen-Induced Airway Eosinophils. Canadian Respiratory Journal, 2002, 9, 26-32.	0.8	11
268	Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-year results of the START study. Respirology, 2006, 11, 767-775.	1.3	11
269	Does the current stepwise approach to asthma pharmacotherapy encourage overâ€treatment?. Respirology, 2010, 15, 596-602.	1.3	11
270	Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge. Proteomics - Clinical Applications, 2012, 6, 476-485.	0.8	11

#	Article	IF	Citations
271	Tiotropium for the treatment of asthma: a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 1115-1124.	1.0	11
272	Emergency department visits and hospitalisations for asthma, COPD and respiratory tract infections: what is the role of respiratory viruses, and return to school in September, January and March?. ERJ Open Research, 2020, 6, 00593-2020.	1.1	11
273	Asthma maintenance and reliever therapy. Annals of Allergy, Asthma and Immunology, 2020, 125, 150-155.	0.5	11
274	A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. Respiratory Medicine, 2022, 201, 106568.	1.3	11
275	In Vitro Effects of Budesonide on Eosinophil-Basophil Lineage Commitment~!2008-03-03~!2008-05-27~!2008-06-13~!. Open Respiratory Medicine Journal, 2008, 2, 60-66.	1.3	11
276	Prolonged asthmatic responses to inhaled methacholine. Journal of Allergy and Clinical Immunology, 1983, 71, 357-362.	1.5	10
277	Isocapnic Hyperventilation for Measuring Airway Hyperresponsiveness in Asthma and in Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1991, 143, 1444-1445.	2.9	10
278	Clinical Models to Compare the Safety and Efficacy of Inhaled Corticosteroids in Patients with Asthma. Canadian Respiratory Journal, 2003, 10, 27-34.	0.8	10
279	Allergen inhalation challenge in smoking compared with non-smoking asthmatic subjects. Clinical and Experimental Allergy, 2011, 41, 1084-1090.	1.4	10
280	Synthesis, Screening and Pharmacokinetic Evaluation of Potential Prodrugs of Bupropion. Part One: In Vitro Development. Pharmaceuticals, 2014, 7, 595-620.	1.7	10
281	Methacholine Challenge: Comparison of Airway Responsiveness Produced by a Vibrating Mesh Nebulizer Versus a Jet Nebulizer. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 88-93.	0.7	10
282	Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel. ERJ Open Research, 2022, 8, 00667-2021.	1.1	10
283	Airway Inflammation and the Pathogenesis of Asthma. Canadian Respiratory Journal, 1994, 1, 189-195.	0.8	9
284	How much is too much? The treatment of mild asthma. European Respiratory Journal, 2007, 30, 403-406.	3.1	9
285	Effects of inhaled fluticasone propionate on CTLAâ€4â€positive CD4+CD25+ cells in induced sputum in mild asthmatics. Respirology, 2008, 13, 1000-1007.	1.3	9
286	Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma. Respiratory Medicine, 2009, 103, 1159-1166.	1.3	9
287	Revisiting early intervention in adult asthma. ERJ Open Research, 2015, 1, 00022-2015.	1.1	9
288	Anti-IgE and Biologic Approaches for the Treatment of Asthma. Handbook of Experimental Pharmacology, 2016, 237, 131-152.	0.9	9

#	Article	IF	Citations
289	Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respiratory Research, 2016, 17, 157.	1.4	9
290	Effect of Magnitude of Airway Responsiveness and Therapy With Inhaled Corticosteroid on Histamine Tachyphylaxis in Asthma. Chest, 1994, 105, 1434-1438.	0.4	8
291	Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 155-162.	2.5	8
292	Tracheobronchomegaly, cough and recurrent chest infection: Mounier-Kuhn syndrome. ERJ Open Research, 2020, 6, 00138-2020.	1.1	8
293	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Safety, 2021, 44, 467-478.	1.4	8
294	Effect of antiâ€Lâ€5 biologics on weight and body mass index. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2913-2916.	2.7	8
295	Bone marrow contribution to eosinophilic inflammation. Memorias Do Instituto Oswaldo Cruz, 1997, 92, 33-35.	0.8	8
296	The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. Allergy, Asthma and Clinical Immunology, 2021, 17, 108.	0.9	8
297	The inhibitory influence of tracheal mucosa mounted in close proximity to canine trachealis. European Journal of Pharmacology, 1990, 178, 85-89.	1.7	7
298	Clinical Relevance of Lipid Mediators in Asthma. Journal of Asthma, 1992, 29, 153-163.	0.9	7
299	The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 293, 251-257.	0.8	7
300	Asthma Management Guidelines: The issue of implementation. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 5-6.	2.5	7
301	Diffuse idiopathic pulmonary neuroendocrine hyperplasia, chronic eosinophilic pneumonia, and asthma. European Respiratory Journal, 2009, 34, 1489-1492.	3.1	7
302	Asthma Pathogenesis. , 2009, , 893-919.		7
303	Introduction. Chest, 2010, 138, 1S-3S.	0.4	6
304	Combination inhaled corticosteroid and long-acting Î²2-agonist use and severe asthma exacerbations. Journal of Allergy and Clinical Immunology, 2012, 129, 1280-1281.	1.5	6
305	Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting Î²2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respiratory Research, 2015, 16, 97.	1.4	6
306	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulmonary Medicine, 2017, 17, 65.	0.8	6

#	Article	IF	Citations
307	Two pathways, one patient; UK asthma guidelines. Thorax, 2018, 73, 797-798.	2.7	6
308	Limosilactobacillus reuteri DSMâ€17938 for preventing cough in adults with mild allergic asthma: A doubleâ€blind randomized placeboâ€controlled crossâ€over study. Clinical and Experimental Allergy, 2021, 51, 1133-1143.	1.4	6
309	Investigations and management of chronic cough: update from the European Respiratory Society Chronic Cough Taskforce 2020. Polish Archives of Internal Medicine, 2020, 130, 789-795.	0.3	6
310	Identifying Molecular Mechanisms of the Late-Phase Asthmatic Response by Integrating Cellular, Gene, and Metabolite Levels in Blood. Annals of the American Thoracic Society, 2016, 13, S98-S98.	1.5	6
311	Exacerbations of Asthma and COPD: Definitions, Clinical Manifestations and Epidemiology. , 2007, 14, 1-11.		5
312	Conclusion. Chest, 2010, 138, 44S-45S.	0.4	5
313	Increased Serum Levels of Soluble IL-18 Receptor Complex in Patients with Allergic Asthma. Allergology International, 2013, 62, 513-515.	1.4	5
314	Spread the Word About CHEST in 2015. Chest, 2015, 147, 1-3.	0.4	5
315	Effects of Asm-024, A Modulator of Acetylcholine Receptor Function, On Airway Responsiveness and Allergen-Induced Responses in Patients with Mild Asthma. Canadian Respiratory Journal, 2015, 22, 230-234.	0.8	5
316	POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes. Chest, 2017, 151, 14-17.	0.4	5
317	Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1397-1400.	2.7	5
318	Identifying a Neurophenotype in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1024-1025.	2.5	5
319	The contribution of FEV ₁ and airflow limitation on the intensity of dyspnea and leg effort during exercise. Insights from a realâ€world cohort. Physiological Reports, 2020, 8, e14415.	0.7	5
320	Language and geographical location influence the incidence of chronic cough in the Canadian Longitudinal Study on Aging. ERJ Open Research, 2022, 8, 00721-2021.	1.1	5
321	Impact of mental health and personality traits on the incidence of chronic cough in the Canadian Longitudinal Study on Aging. ERJ Open Research, 2022, 8, 00119-2022.	1.1	5
322	Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma. Respiratory Medicine, 2008, 102, 77-81.	1.3	4
323	The pharmacological modulation of allergen-induced asthma. Inflammopharmacology, 2013, 21, 113-124.	1.9	4
324	Surfactant Protein-D and Asthma. Chest, 2016, 149, 1121-1122.	0.4	4

#	Article	IF	Citations
325	Cholinergic synapse pathway gene polymorphisms associated with allergen-induced late asthmatic responses. ERJ Open Research, 2019, 5, 00107-2019.	1.1	4
326	Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction. Journal of Asthma, 2020, 57, 431-440.	0.9	4
327	Influence of age, sex and respiratory viruses on the rates of emergency department visits and hospitalisations with respiratory tract infections, asthma and COPD. ERJ Open Research, 2021, 7, 00053-2021.	1.1	4
328	Obstructive Lung Disease from Conception to Old Age: Differences in the Treatment of Adults and Children with Asthma. Proceedings of the American Thoracic Society, 2009, 6, 720-723.	3.5	3
329	Asthma in the real world. Journal of Allergy and Clinical Immunology, 2013, 132, 70-71.	1.5	3
330	Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler Â® devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design. Pulmonary Pharmacology and Therapeutics, 2017, 44, 1-6.	1.1	3
331	Exercise-induced bronchoconstriction and bronchodilation: investigating the effects of age, sex, airflow limitation and FEV1. European Respiratory Journal, 2021, 58, 2004026.	3.1	3
332	Medical algorithms: Approach to adult asthma exacerbations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3556-3559.	2.7	3
333	In Vitro Airway Responsiveness of Flinders Sensitive and Resistant Line Rats. Brain, Behavior, and Immunity, 2000, 14, 62-67.	2.0	2
334	Initiation, Dose Reduction, and Duration of Inhaled Corticosteroid Therapy. Immunology and Allergy Clinics of North America, 2005, 25, 511-521.	0.7	2
335	Asthma maintenance and reliever therapy. Annals of Allergy, Asthma and Immunology, 2012, 109, 388-391.	0.5	2
336	Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug. Pharmaceuticals, 2014, 7, 676-694.	1.7	2
337	Timing is everything: Targeting IgE to reduce asthma exacerbation risk. Journal of Allergy and Clinical Immunology, 2015, 136, 1486-1487.	1.5	2
338	Targeting Eosinophils in Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1985-1986.	13.9	2
339	Type 2 innate lymphoid cells expressing death receptor 3 are increased in airway of mild atopic asthmatic subject following allergen inhalation challenge. Journal of Allergy and Clinical Immunology, 2018, 141, AB285.	1.5	2
340	Use of a vibrating mesh nebulizer for allergen challenge. Allergy, Asthma and Clinical Immunology, 2019, 15, 73.	0.9	2
341	A golden age of asthma research. European Respiratory Journal, 2020, 56, 2003820.	3.1	2
342	Response of upper and lower airway inflammation to bronchial challenge with house dust mite in Chinese asthmatics: a pilot study. Journal of Thoracic Disease, 2021, 13, 4988-4998.	0.6	2

#	Article	IF	Citations
343	Cellular and Mediator Mechanisms of the Early-Phase Response. , 2006, , 375-387.		2
344	Comparison of Isocapnic Hyperventilation and Histamine or Methacholine Inhalation for the Assessment of Airway Responsiveness. Allergy and Asthma Proceedings, 1989, 10, 317-321.	1.0	1
345	Rebuttal from Dr. O'Byrne. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 414-415.	2.5	1
346	Pharmacia Allergy Research Foundation and its Award for Young Scientists in Allergy Research. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 269-270.	2.7	1
347	The promise of electronic data capture in respiratory medicine. European Respiratory Journal, 2011, 37, 228-230.	3.1	1
348	The airway epithelium in childhood asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 998-999.	1.5	1
349	Blood biomarkers of the late phase asthmatic response using RNA-Seq. Allergy, Asthma and Clinical Immunology, 2014, 10, .	0.9	1
350	Evolving Concepts in Asthma. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 001-002.	0.8	1
351	Inhaled corticosteroids/formoterol as a reliever in mild asthma. Respirology, 2020, 25, 795-796.	1.3	1
352	Effect of Inhaled Prostaglandin E2on Methacholine and Leukotriene D4Airway Responsiveness in Asthmatic Subjects. Canadian Respiratory Journal, 1996, 3, 165-168.	0.8	0
353	Formoterol was more effective than terbutaline when taken as needed for moderate to severe asthma. Evidence-Based Medicine, 2001, 6, 105-105.	0.6	0
354	Prescribing Records and the First Amendment. New England Journal of Medicine, 2009, 361, 209-210.	13.9	0
355	Asthma: management of severe disease. Lancet Respiratory Medicine,the, 2013, 1, e3-e4.	5.2	0
356	A 43-year-old man with cough, expectoration and recurrent wheezing. Journal of Thoracic Disease, 2016, 8, 3468-3477.	0.6	0
357	Allergen-Induced Increase in Group 2 Innate Lymphoid Cells in the Airways of Mild Asthmatics. Journal of Allergy and Clinical Immunology, 2016, 137, AB178.	1.5	0
358	Rebuttal From Dr Oâ€™Byrne. Chest, 2017, 151, 20-21.	0.4	0
359	Giants in Chest Medicine. Chest, 2018, 153, 776-777.	0.4	0
360	Expression profile of IL-33/ST2 and TSLP/TSLP-R in the skin of atopic dermatitis post-allergen exposure. Journal of Allergy and Clinical Immunology, 2018, 141, AB187.	1.5	0

#	Article	IF	Citations
361	Type 2 Innate Lymphoid Cells and Eosinophil Progenitor Cells are Preferentially Increased in Lesional Skin of Subjects with Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 2018, 141, AB293.	1.5	0
362	Group 2 innate lymphoid cells in patients with nonasthmatic eosinophilic bronchitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 649-652.	2.7	0
363	Asthma outcome measures. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 201-203.	1.1	0
364	Experimental Models of Airway Hyperresponsiveness. , 2005, , 1403-1414.		0
365	Mechanisms and Management of Exercise-Induced Bronchoconstriction. , 2009, , 171-186.		0
366	New treatment approaches for asthma. Polish Archives of Internal Medicine, 2013, 123, 11-13.	0.3	0
367	Inhaled Î²2-Agonists. , 2014, , 1534-1541.		0
368	Reply to â€œAs-needed budesonide-formoterol for adolescents with mild asthma: importance of lung functionâ€• Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4179-4180.	2.0	0
369	Eosinophil Progenitors in Patients With Non-Asthmatic Eosinophilic Bronchitis, Eosinophilic Asthma, and Normal Controls. Frontiers in Immunology, 2022, 13, 737968.	2.2	0